Vaxart (VXRT) Corporate presentation summary

Transformative oral vaccine platform

• Oral pill vaccine platform induces both systemic and mucosal immunity, potentially offering broader protection than injectable vaccines.

• Thermostable oral format enables easier distribution and self-administration, reducing cold chain and access barriers.

• Platform validated by Dynavax partnership, extending cash runway into Q2 2027.

• Manufacturing is fully based in the United States.

Clinical pipeline and key programs

• Pipeline includes programs for COVID-19, norovirus, and influenza, with BARDA-funded studies providing head-to-head efficacy data.

• COVID-19 oral vaccine in Phase 2b, with ~5,400 subjects enrolled; topline data for 400-subject cohort expected Q2 2026, main cohort in early 2027.

• Norovirus program advancing to Phase 2b, with second-generation candidate showing improved antibody responses.

• Influenza oral vaccine demonstrated at least comparable protection to market-leading injectable in Phase 2 challenge.

Efficacy and immunogenicity highlights

• Second-generation norovirus vaccine showed significant increases in GI.1 (+141%) and GII.4 (+94%) neutralizing antibodies compared to first-generation.

• Significant improvements in fecal IgA for both GI.1 (+73%) and GII.4 (+90%) with second-generation norovirus candidate.

• Influenza oral vaccine reduced viral shedding and showed favorable safety profile; H5N1 program demonstrated 100% survival in animal model.